Table 2 Crude incidence rate and HR (95%CI) of clinical outcomes according to HBsAb status
Clinical outcomes | Metrics | Total | HBsAb-negative group | HBsAb-positive group | Unadjusted model | Adjusted model | ||
|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |||||
HBsAg loss | PYs of follow-up | 719.93 | 575.76 | 144.17 | 2.21(1.59–3.08) | < 0.001 | 1.78(1.29–2.48) | 0.001 |
No. of events | 154 | 100 | 54 | |||||
Crude incidence rate (per 100 PY) | 21.40 | 17.37 | 37.46 | |||||
HR (95% CI) | - | 1(Ref) | 2.16(1.52–3.03) | |||||
HBeAg clearance | PYs of follow-up | 568.73 | 453.60 | 115.13 | 1.85(1.35–2.53) | < 0.001 | 1.78(1.25–2.53) | 0.001 |
No. of events | 187 | 130 | 57 | |||||
Crude incidence rate (per 100 PY) | 32.88 | 28.66 | 49.51 | |||||
HR (95% CI) | - | 1(Ref) | 1.73(1.24–2.38) | |||||
HBV DNA undetectability | PYs of follow-up | 407.95 | 327.61 | 80.34 | 1.51(1.15–1.96) | 0.003 | 1.27(0.95–1.69) | 0.104 |
No. of events | 292 | 218 | 74 | |||||
Crude incidence rate (per 100 PY) | 71.58 | 66.54 | 92.11 | |||||
HR (95% CI) | - | 1(Ref) | 1.38(1.05–1.81) | |||||